Engineering Psychedelics: $22M Pool For Clinical Trials Of Compounds Targeting CNS Disorders

October 20, 2022 · Bezinga

NYC and Cambridge-based Empyrean Neuroscience Inc. is a new genetic engineering company developing neuroactive compounds for neuropsychiatric and neurological disorders launching with a $22 million Series A financing.

The company’s CEO is long-time biotech executive Dr. Usman “Oz” Azam, joined by Dr. Fred Grossman as chief medical officer. Azam has previously worked on genetic engineering with Dr. Carl June of the University of Pennsylvania, while Grossman is a psychiatrist that holds expertise in CNS-targeted small molecules development.

Both leadmen say the goal is to target the demand gap within the mental health disorders scenario. “The best treatment available in psychiatry over the past 50 years is less than 50% effective,” stated Dr. Grossman.

This is how you can potentially earn $3,000 in extra income every single month…

Former leading hedge-fund trader Chris Capre is the real deal. With his simple options trading strategy, he’s helping thousands of traders by sharing his trade signals in real-time. Click Here to Get his Trades for only $0.99. ⭐⭐⭐⭐⭐ “My only regret is I wish I joined earlier…”

Dr. Azam echoed the comment: “There is an enormous medical need for safe and effective therapeutics that treat neuropsychiatric and neurologic disorders and we believe genetic engineering provides the answer.

“By applying our genetic engineering platform to make precise modifications to the genomes of fungi and plants, we can change the amount and kind of neuroactive small molecules they produce, with the goal of developing safe and effective treatments for difficult-to-treat diseases of the CNS.” 

The initial funding will be used to create small molecule therapeutics through precision genetic modification, transformation and regeneration of fungi and plants with potential therapeutic properties for CNS disorders, with initial focus set on Major Depressive Disorder (MDD) and then moving on to PTSD, substance abuse and dependence, chronic pain and neurological disorders as a whole.

Reuniting the work of plant biologists and genetic engineers, Empyrean is setting out a homegrown technology without licensing out academic IP for plants and fungi, a new class of therapeutics they named “mycogenomic” and “phytogenomic” molecules. Its developmental pipeline includes fungal alkaloids, cannabinoids and other neuroactive compounds such as DMT. 

Dr. Grossman further explained the company’s standpoint: “Fungal alkaloids and cannabinoids have shown promise in treating depression, PTSD, anxiety, and other neuropsychiatric and neurologic disorders. We believe our approach of genetically engineering fungi and plants can improve their safety and efficacy and will ultimately help to address the substantial unmet medical need in patients who suffer from these diseases.”

IND-enabling studies of Empyrean’s first genetically-engineered encapsulated mushroom drug product are currently underway, and the company expects to enter clinical trials for MDD in 2023. Moreover, it has licensed CRISPR/Cas9 technology from ERS Genomics for genetic engineering applications related to its therapeutic pipeline. 

Details On The Novel Gene Technology Application

In a recent interview, Azam explained: “The whole premise is applying genetic engineering technology that we use in oncology and T-cell engineering to species of fungi and plants for creating a whole new class of therapies. We don’t know anybody else doing this with the focus on neuropsychiatry and neurology.”

What makes Empyrean’s approach different from other companies extracting neuroactive compounds is that the company is set to take advantage of other natural compounds present in fungi and plants. For instance mushrooms, besides psilocybin, have alkaloids compounds present in them, which hold an “entourage effect” that “may allow for these alkaloids to enhance the clinical effect that we would expect from psilocybin,” Dr. Grossman explained.

“This platform is so exciting because you can apply genetic engineering and create concentrations of effective neuroactive molecules in plants and fungi that have never been seen before. We’ve never seen this in psychiatry, and that’s why everyone is leaning in,” he saidFull Story

In categories:Psychedelics Research
Next Post

Giving a Whole New Meaning to 'Get Lite' - Psychedelics Light Up the Neuropathways in the Brain According to a New Medical Study

Brand New Study Shows How Psychedelics Light Up Neuropathways In The Brain - More Fascinating Insight Into How Psychedelics Work Psychedelics are all the rage right now. And for good reason: these trippy substances have so much more therapeutic value than…
Previous Post

Pennsylvania Launches $200,000 Grant Program To Support Hemp Marketing And Consumer Awareness

Pennsylvania officials announced on Monday that they will be providing up to $200,000 in matched funding for marketing projects to promote the state’s hemp market. The state Department of Agriculture said that non-profit organizations that take on marketing initiatives to…
Random Post

CBD Slows the Aging Process Says a New Study, So When Should You Start Taking It?

Why It Isn’t Too Early To Use CBD For Preventing The Detrimental Effects Of Aging Realizing that you’re getting old can be a tough process. For some, it comes with cracks and pains with even the slightest movements. For others,…
Random Post

Texas bill would allow cities and counties to make call on whether to legalize cannabis

Adults 21 and over could possess up to 2.5 ounces of pot, including up to 15 grams of cannabis concentrates, under the bill. As Texas continues to lag behind the rest of the country in cannabis reform, a Democrat in the Texas…
Random Post

Are antiquated marijuana policies exacerbating supply chain issues?

Tens of thousands of commercial truckers are leaving their jobs, resulting in higher prices and barren shelves. What’s motivating this mass exodus? Look no further than the federal government’s outdated policies toward marijuana.  Despite the reality that state governments have legalized cannabis…
Random Post

Study: Cannabis Legalization Does Not Lead to Increased Use of Other Drugs

A new report found cannabis legalization does not lead to an increase in substance use disorders or the increased use of illicit drugs. Cannabis legalization had not led to an increase in substance use disorders or increased use of other…